DelveInsight’s, “Coronary Artery Disease Pipeline Insight 2023” report provides comprehensive insights about 30+ Coronary Artery Disease companies and 30+ pipeline drugs in the Coronary Artery Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. The Coronary Artery Disease pipeline report also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Coronary Artery Disease Emerging drugs, the Coronary Artery Disease pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Coronary Artery Disease pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Coronary Artery Disease Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Coronary Artery Disease clinical trials studies, Coronary Artery Disease NDA approvals (if any), and product development activities comprising the technology, Coronary Artery Disease collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Coronary Artery Disease Pipeline Report
Request a sample and discover the recent breakthroughs happening in the Coronary Artery Disease Pipeline landscape @ Coronary Artery Disease Pipeline Outlook Report
Coronary Artery Disease Overview
Coronary artery disease (CAD) is the most common type of heart disease in the United States. It is sometimes called coronary heart disease or ischemic heart disease. Coronary Artery Disease is caused by plaque buildup in the walls of the arteries that supply blood to the heart (called coronary arteries) and other parts of the body.Plaque is made up of deposits of cholesterol and other substances in the artery. Plaque buildup causes the inside of the arteries to narrow over time, which can partially or totally block the blood flow.
Recent Developmental Activities in the Coronary Artery Disease Treatment Landscape
For further information, refer to the detailed Coronary Artery Disease Drugs Launch, Coronary Artery Disease Developmental Activities, and Coronary Artery Disease News, click here for Coronary Artery Disease Ongoing Clinical Trial Analysis
Coronary Artery Disease Emerging Drugs Profile
Selatogrel, is a small molecule being developed by Idorsia Pharmaceuticals. It acts as a P2Y12 receptor antagonist. Currently, the drug is being studied in Phase II stage of Clinical trial evaluation for the treatment of Coronary artery disease.
Atuliflapon (formerly AZD 5718) is an orally available, small molecule, 5-lipoxygenase activating protein inhibitor, being developed by AstraZeneca. Currently, the drug is being studied in Phase II stage of clinical trial evaluation for the treatment of Coronary artery disease.
XTR003 is a PET imaging radiopharmaceutical agent used to trace myocardial fatty acid metabolism. XTR003 is a modified fatty acid that enters the myocytes and passes through mitochondrial membrane by the same process as the natural existing fatty acids and then undergoes partial β-oxidation before being trapped in the mitochondria. In preclinical study XTR003 showed high myocardial uptake and retention. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Coronary Artery Disease.
Coronary Artery Disease Pipeline Therapeutics Assessment
There are approx. 30+ key Coronary Artery Disease companies which are developing the therapies for Coronary Artery Disease. The companies which have their Coronary Artery Disease drug candidates in the most advanced stage, i.e. Phase II include, Idorsia Pharmaceuticals.
Find out more about the Coronary Artery Disease Pipeline Segmentation, Therapeutics Assessment, and Coronary Artery Disease Emerging Drugs @ Coronary Artery Disease Treatment Landscape
Scope of the Coronary Artery Disease Pipeline Report
Dive deep into rich insights for drugs for Coronary Artery Disease Pipeline Companies and Therapies, click here @ Coronary Artery Disease Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Coronary Artery Disease Mergers and acquisitions, Coronary Artery Disease Licensing Activities @ Coronary Artery Disease Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsightContact Person: Yash BhardwajEmail: Send EmailPhone: +91 9568243403Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/